nabilone

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Value	Reference
BA (Bioavailability)	20 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	4.947		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	1.923		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.887	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	39.902	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	0.220	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	0.240	%	High	1
herg	hERG pIC50	5.051	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	31.842	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	63.096	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	0.600	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70	54
kinase-selectivity-class	EIF2AK3,GRK2	2
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.457		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	72.611		High	1
mppb	Mouse plasma protein binding (% unbound)	0.470		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.632		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	0.240	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	86.298	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	0.410	%	High	1
rppb	Rat plasma protein binding (% unbound)	0.440	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	1.698	uM	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
White blood cell count abnormal	354.91	23.56	84	5445	7420	90615498
Somatic symptom disorder	129.16	23.56	32	5497	3409	90619509
Musculoskeletal stiffness	128.01	23.56	121	5408	296411	90326507
Sacroiliitis	127.53	23.56	33	5496	4186	90618732
Gait disturbance	125.41	23.56	113	5416	260383	90362535
Rheumatoid arthritis	105.91	23.56	120	5409	362494	90260424
Insomnia	89.98	23.56	106	5423	333368	90289550
Drug hypersensitivity	82.48	23.56	120	5409	463489	90159429
Mood altered	82.04	23.56	33	5496	17111	90605807
Mean cell haemoglobin concentration abnormal	74.33	23.56	12	5517	136	90622782
Acute psychosis	73.59	23.56	20	5509	3058	90619860
Pain	70.97	23.56	174	5355	996167	89626751
Therapeutic product effect incomplete	70.20	23.56	72	5457	193824	90429094
Lip and/or oral cavity cancer	68.87	23.56	15	5514	907	90622011
Therapeutic response shortened	63.50	23.56	30	5499	22849	90600069
Cognitive disorder	61.04	23.56	43	5486	69364	90553554
Occult blood	58.41	23.56	14	5515	1297	90621621
Cannabinoid hyperemesis syndrome	52.76	23.56	8	5521	58	90622860
Anaphylactic reaction	52.17	23.56	43	5486	87481	90535437
Thyroid cancer	47.87	23.56	17	5512	6267	90616651
Psychotic disorder	43.91	23.56	26	5503	31204	90591714
Dystonia	43.46	23.56	21	5508	16798	90606120
Ankylosing spondylitis	32.73	23.56	16	5513	13117	90609801
Blood pressure increased	31.97	23.56	49	5480	197168	90425750
Iron deficiency	31.02	23.56	14	5515	9598	90613320
Dyskinesia	30.64	23.56	22	5507	36512	90586406
Eyelid haematoma	28.97	23.56	5	5524	87	90622831
Lichen sclerosus	28.62	23.56	8	5521	1355	90621563
Orthostatic hypotension	25.85	23.56	21	5508	41806	90581112
Eyelid injury	25.65	23.56	5	5524	174	90622744
Spinal osteoarthritis	24.48	23.56	15	5514	19133	90603785
Strabismus	23.94	23.56	8	5521	2460	90620458
Aplastic anaemia	23.92	23.56	13	5516	13256	90609662

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inspiratory capacity decreased	456.90	48.70	90	2930	2877	42615438
Pelvic pain	192.89	48.70	45	2975	3209	42615106
Terminal insomnia	166.55	48.70	32	2988	887	42617428
Injection site warmth	132.39	48.70	32	2988	2651	42615664
Kidney infection	103.06	48.70	32	2988	6738	42611577
Oral herpes	99.65	48.70	32	2988	7512	42610803
Neck pain	97.86	48.70	46	2974	29968	42588347
Ocular hyperaemia	96.91	48.70	38	2982	15925	42602390
Injection site mass	95.62	48.70	32	2988	8543	42609772
Musculoskeletal pain	93.25	48.70	46	2974	33294	42585021
Burning sensation	83.58	48.70	37	2983	20976	42597339
Dry eye	77.15	48.70	32	2988	15474	42602841
Injection site reaction	76.72	48.70	32	2988	15689	42602626
Drug ineffective	73.36	48.70	146	2874	630051	41988264
Feeling hot	70.42	48.70	34	2986	23448	42594867
Injection site erythema	69.02	48.70	32	2988	20163	42598152
Back pain	65.04	48.70	64	2956	141712	42476603
Chest injury	56.49	48.70	15	3005	1807	42616508
Pain	52.70	48.70	75	2945	244773	42373542
Cardiac disorder	49.55	48.70	35	2985	48897	42569418

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inspiratory capacity decreased	377.46	22.99	75	7648	2520	110579056
Terminal insomnia	148.59	22.99	33	7690	1905	110579671
Somatic symptom disorder	127.55	22.99	32	7691	3127	110578449
Pelvic pain	122.71	22.99	45	7678	15897	110565679
Sacroiliitis	117.67	22.99	33	7690	4945	110576631
Kidney infection	80.03	22.99	38	7685	25561	110556015
Injection site warmth	77.23	22.99	33	7690	17372	110564204
Injection site mass	72.27	22.99	35	7688	24578	110556998
Mood altered	70.72	22.99	33	7690	21342	110560234
Ankylosing spondylitis	70.59	22.99	30	7693	15582	110565994
Ocular hyperaemia	67.35	22.99	39	7684	39247	110542329
Lip and/or oral cavity cancer	63.03	22.99	15	7708	1175	110580401
Burning sensation	62.59	22.99	46	7677	69166	110512410
Acute psychosis	61.38	22.99	20	7703	4967	110576609
Oral herpes	59.68	22.99	35	7688	36045	110545531
Therapeutic response shortened	57.81	22.99	32	7691	29551	110552025
Musculoskeletal pain	55.32	22.99	66	7657	182957	110398619
Mean cell haemoglobin concentration abnormal	55.13	22.99	10	7713	203	110581373
Therapeutic product effect incomplete	53.82	22.99	72	7651	223733	110357843
Occult blood	51.69	22.99	14	7709	1842	110579734
Cannabinoid hyperemesis syndrome	49.11	22.99	8	7715	83	110581493
Cognitive disorder	49.06	22.99	44	7679	87467	110494109
Neck pain	48.51	22.99	51	7672	123079	110458497
Drug ineffective	46.55	22.99	219	7504	1520321	109061255
Thyroid cancer	45.81	22.99	17	7706	6197	110575379
Dry eye	45.80	22.99	35	7688	55758	110525818
Drug ineffective for unapproved indication	44.86	22.99	45	7678	102793	110478783
Feeling hot	43.71	22.99	42	7681	91064	110490512
Back pain	42.12	22.99	85	7638	370911	110210665
Blood pressure increased	41.76	22.99	69	7654	258304	110323272
Chest injury	39.25	22.99	13	7710	3396	110578180
Cardiac disorder	38.17	22.99	36	7687	76244	110505332
Pain	36.30	22.99	147	7576	954808	109626768
Arthralgia	36.22	22.99	128	7595	779504	109802072
Injection site erythema	35.29	22.99	38	7685	94138	110487438
Musculoskeletal stiffness	34.01	22.99	66	7657	279756	110301820
Dystonia	32.39	22.99	21	7702	25784	110555792
Injection site reaction	31.74	22.99	35	7688	89035	110492541
Psychotic disorder	31.32	22.99	27	7696	50910	110530666
Immune-mediated hepatitis	30.68	22.99	13	7710	6698	110574878
Incorrect dose administered	30.67	22.99	37	7686	103604	110477972
Joint swelling	29.06	22.99	82	7641	442763	110138813
Lichen sclerosus	28.77	22.99	8	7715	1160	110580416
Lower respiratory tract congestion	27.75	22.99	11	7712	4785	110576791
Strabismus	27.37	22.99	10	7713	3489	110578087
Eyelid haematoma	26.80	22.99	5	7718	119	110581457
Malaise	26.72	22.99	105	7618	671714	109909862
Eyelid injury	24.73	22.99	5	7718	183	110581393
Heart rate increased	24.00	22.99	39	7684	143795	110437781
Aplastic anaemia	23.88	22.99	17	7706	24291	110557285
Rash	23.72	22.99	14	7709	820950	109760626
Body temperature decreased	23.56	22.99	20	7703	36915	110544661

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

nabilone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Source	Code	Description
ATC	A04AD11	ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Other antiemetics
FDA CS	M0003267	Cannabinoids
MeSH PA	D000932	Antiemetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D018373	Peripheral Nervous System Agents
FDA EPC	N0000175782	Cannabinoid
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:48407	antiparkinson drug
CHEBI has role	CHEBI:50919	antiemetic
CHEBI has role	CHEBI:74518	anti-obesity agent

Disease	Relation	SNOMED_ID	DOID
Chemotherapy-induced nausea and vomiting	indication	236084000
Depressive disorder	contraindication	35489007
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Schizophrenia	contraindication	58214004	DOID:5419
Hepatic failure	contraindication	59927004
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Mania	contraindication	231494001
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Cannabinoid receptor 1	GPCR	P21554	CNR1_HUMAN	AGONIST	Ki	8.40	CHEMBL	CHEMBL
Cannabinoid receptor 2	GPCR	P34972	CNR2_HUMAN		Ki	8.20	CHEMBL
Cannabinoid receptor 1	GPCR		CNR1_RAT		Ki	8.66	CHEMBL
Cannabinoid receptor 2	GPCR		CNR2_MOUSE		Ki	8.74	CHEMBL

ID	Source
4019352	VUID
N0000147524	NUI
D05099	KEGG_DRUG
4019352	VANDF
C0068333	UMLSCUI
CHEBI:135574	CHEBI
CHEMBL2218896	ChEMBL_ID
DB00486	DRUGBANK_ID
C011941	MESH_SUPPLEMENTAL_RECORD_UI
5284592	PUBCHEM_CID
9071	IUPHAR_LIGAND_ID
3930	INN_ID
2N4O9L084N	UNII
31447	RXNORM
15778	MMSL
38357	MMSL
52672	MMSL
d04587	MMSL
001686	NDDF
322124005	SNOMEDCT_US
395806009	SNOMEDCT_US
2N4O9L084N	INXIGHT DRUGS